Cargando…

Standardized two-step testing of antibody activity in COVID-19 convalescent plasma

The COVID-19 pandemic revealed an urgent need for rapid profiling of neutralizing antibody responses and development of antibody therapeutics. The current Food and Drug Administration-approved serological tests do not measure antibody-mediated viral neutralization, and there is a need for standardiz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gilchuk, Pavlo, Thomsen, Isaac, Yoder, Sandra, Brady, Eric, Chappell, James D., Stevens, Laura J., Denison, Mark R., Sutton, Rachel E., Chen, Rita E., VanBlargan, Laura A., Suryadevara, Naveenchandra, Zost, Seth J., Schmitz, Jonathan, Pulley, Jill M., Diamond, Michael S., Rhoads, Jillian P., Bernard, Gordon R., Self, Wesley H., Rice, Todd W., Wheeler, Allison P., Crowe, James E., Carnahan, Robert H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653399/ https://www.ncbi.nlm.nih.gov/pubmed/34901783 http://dx.doi.org/10.1016/j.isci.2021.103602

Ejemplares similares

Real-time cell analysis: A high-throughput approach for testing SARS-CoV-2 antibody neutralization and escape
por: Suryadevara, Naveenchandra, et al.
Publicado: (2022)

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
por: Suryadevara, Naveenchandra, et al.
Publicado: (2021)

Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
por: Chen, Elaine C., et al.
Publicado: (2021)

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
por: VanBlargan, Laura, et al.
Publicado: (2021)

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
por: VanBlargan, Laura A., et al.
Publicado: (2022)

Response
por: Self, Wesley H., et al.
Publicado: (2022)

An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer
por: Suryadevara, Naveenchandra, et al.
Publicado: (2022)

Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled Trial
por: Self, Wesley H., et al.
Publicado: (2022)

SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies
por: Diamond, Michael, et al.
Publicado: (2021)

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition
por: Greaney, Allison J., et al.
Publicado: (2020)

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
por: Greaney, Allison J., et al.
Publicado: (2021)

A high-throughput liquid bead array assay confirms strong correlation between SARS-CoV-2 antibody level and COVID-19 severity
por: Bennett, Monique, et al.
Publicado: (2021)

A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques
por: Cobb, Ronald R., et al.
Publicado: (2022)

Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development
por: Murin, Charles D., et al.
Publicado: (2022)

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
por: Diamond, Michael, et al.
Publicado: (2021)

A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis
por: Goo, Leslie, et al.
Publicado: (2017)

A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein
por: Mousa, Jarrod J., et al.
Publicado: (2017)

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
por: Winkler, Emma S., et al.
Publicado: (2021)

An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections
por: VanBlargan, Laura A., et al.
Publicado: (2018)

A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope
por: VanBlargan, Laura A., et al.
Publicado: (2021)

SARS-CoV-2 antibodies from children exhibit broad neutralization and belong to adult public clonotypes
por: Wall, Steven C., et al.
Publicado: (2023)

Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma
por: Gilchuk, Pavlo, et al.
Publicado: (2021)

REINFORCEMENT OF CONVALESCENT ANTIPOLIOMYELITIC SERUM IN THE MONKEY
por: Rhoads, C. P.
Publicado: (1931)

Antiviral protection by antibodies targeting the glycan cap of Ebola virus glycoprotein requires activation of the complement system
por: Bukreyev, Alexander, et al.
Publicado: (2023)

Potently neutralizing and protective human antibodies against SARS-CoV-2
por: Zost, Seth J., et al.
Publicado: (2020)

A budding new approach strengthens an important message
por: Zost, Seth J., et al.
Publicado: (2023)

The Type-Specific Neutralizing Antibody Response Elicited by a Dengue Vaccine Candidate Is Focused on Two Amino Acids of the Envelope Protein
por: VanBlargan, Laura A., et al.
Publicado: (2013)

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
por: Dong, Jinhui, et al.
Publicado: (2021)

Using a multicultural and multilingual awareness-raising strategy to enhance enrollment of racially underrepresented minoritized communities – the PassITON trial
por: Bell, Jasmine, et al.
Publicado: (2022)

Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
por: Self, Wesley H., et al.
Publicado: (2021)

Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
por: Self, Wesley H., et al.
Publicado: (2021)

Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition
por: Kramer, Kevin J., et al.
Publicado: (2021)

IMMUNITY FOLLOWING THE INJECTION OF MONKEYS WITH MIXTURES OF POLIOMYELITIS VIRUS AND CONVALESCENT HUMAN SERUM
por: Rhoads, C. P.
Publicado: (1931)

Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes
por: Chen, Elaine C., et al.
Publicado: (2023)

Human antibody recognition of H7N9 influenza virus HA following natural infection
por: Gilchuk, Iuliia M., et al.
Publicado: (2021)

Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell
por: Puray-Chavez, Maritza, et al.
Publicado: (2021)

Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking
por: Shiakolas, Andrea R., et al.
Publicado: (2022)

A Powassan virus domain III nanoparticle immunogen elicits neutralizing and protective antibodies in mice
por: Malonis, Ryan J., et al.
Publicado: (2022)

Human monoclonal antibodies against Ross River virus target epitopes within the E2 protein and protect against disease
por: Powell, Laura A., et al.
Publicado: (2020)

Response to Comment: Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines Against COVID-19 Hospitalizations
por: Lewis, Nathaniel M, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_erei7d9mfij9o5r8s3904b2slg